Ipilimumab 5mg/mL Concentrate for Solution for Infusion

Prescriber Criteria: Consultant Haematologist
Consultant Oncologist

Inpatient use:

- ***Melanoma***

- As monotherapy or in combination with nivolumab for the treatment of advanced (unresectable or metastatic) melanoma in adults.
- As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adolescents 12 years of age and older.

- ***Non-small cell lung cancer (NSCLC)***
  In combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of metastatic NSCLC in adults whose tumours have no sensitising EGFR mutation or ALK translocation.

- ***Malignant pleural mesothelioma (MPM)***
  In combination with nivolumab for the first-line treatment of adult patients with unresectable MPM.

- ***Renal cell carcinoma (RCC)***
  In combination with nivolumab for the first-line treatment of adult patients with intermediate/poor-risk advanced RCC.

- ***Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)***
  In combination with nivolumab for the treatment of adult patients with dMMR or MSI-H CRC after prior fluoropyrimidine-based combination chemotherapy.

- ***Oesophageal squamous cell carcinoma (OSCC)***
  In combination with nivolumab for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic OSCC with tumour cell PD-L1 expression ≥1%.

Duration of Approval:
1 year